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ABSTRACT

Amelioration of Chikungunya through Inhibition of
the Inflammatory Response
by
Ashley L. Dagley, Master of Science
Utah State University, 2016
Major Professor: Dr. Justin G. Julander
Department: Animal, Dairy and Veterinary Sciences
Chikungunya (CHIK) is an emerging viral di7sease, which causes
significant morbidity and mortality throughout tropical/subtropical areas of
the world, including a recent outbreak in the Americas. Disease typically
includes fever, rash, and arthritis. Joint involvement is generally selflimiting, but infection with Chikungunya virus (CHIKV) can lead to chronic
debilitating arthritis that can last for months to years. With no vaccine and
no licensed treatment, suitable animal models of CHIKV are needed to test
intervention strategies. We developed a model of CHIK in DBA1/J mice that
develop joint swelling, increase in inflammatory cytokines and
splenomegaly in mice, which include important symptoms of disease seen in
infected humans. We used this model to test the hypothesis that treatment
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with immune-modulatory compounds would ameliorate disease. GP1681,
which suppresses TNF-α, IL-1β, and IL-6, exacerbated CHIK as indicated
by increased footpad swelling and viral load. Prophylactic treatment with
mDEF201, an adenovirus-vectored interferon, reduced disease, including
joint swelling, virus titers at the site of virus challenge and inflammatory
cytokines (IL-6, MCP-1, MIP-1α, and RANTES), although efficacy waned
as treatment initiation was extended beyond virus challenge. Methotrexate
treatment was also effective at ameliorating joint swelling and other disease
parameters. Actemra (ACT), an anti-IL-6 antibody, reduced IL-6 levels to
baseline, although the resulting improvement in footpad swelling was not
significant. Combination therapy with methotrexate and ACT resulted in
reduced footpad swelling. Based on our results, immune modulators have
potential for the treatment of CHIKV and some of the compounds tested
might have potential for clinical developmental.
(100 pages)
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PUBLIC ABSTRACT

Amelioration of Chikungunya through Inhibition of
the Inflammatory Response
Ashley L. Dagley
CHIK is an emerging viral disease that is rapidly spreading around the
world and causing significant illness in infected people. This virus is spread
through the bite of an infected mosquito. Symptoms of disease include high
fever, rash, joint pain and arthritis-like symptoms. This disease has recently
been reported in the United States, mainly as a result of importation from
vacationers to areas affected by this disease. The purpose of this research
was to model the disease in mice in order to identify intervention strategies
that reduce disease in the hope that it will be useful in the treatment of
infected humans. To do this we characterized disease in an animal model
that supported virus growth and displayed important signs of disease similar
to those seen in infected human patients. Mice developed swollen footpads
after inoculation of virus into the footpad. Microscopic examination also
revealed signs of muscle disease.
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The therapeutic interventions we chose to test in the mouse model
included mDEF201, GP1681, an IL-6 antibody (ACT) and methotrexate.
Disease was either improved, made worse, or was unaffected, depending on
the treatment administered. We demonstrated activity of mDEF201 and
methotrexate in improving disease in mice, while ACT showed a slight trend
towards improvement and GP1681 made the disease worse. The model
appeared to be suitable in identifying active compounds, but further research
needs to be done to verify these benefits in a clinical setting.
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1. INTRODUCTION

Originally described in a 1955 epidemiology report, Chikungunya
(CHIK) roughly translates in Makonde to “that which bends up” (Ross,
1956) in reference to the stooped posture developed as a result of the
arthritic symptoms of the disease (Seijo et al., 2014). This typically selflimiting disease occurs after infection with Chikungunya virus (CHIKV),
which is spread by mosquitoes and probably originated in Central/East
Africa where it circulates in a sylvatic cycle between mosquitoes and
nonhuman primates (NHPs).
The arthralgia associated with CHIK can be debilitating. Recent
adaptive mutations of this virus (Wasonga et al., 2015) include improved
host immune system evasion and adaptation to different mosquito vectors
(Kumar et al., 2014). Such changes are linked to the rise in mortality rate
from rare (Mavalankar et al., 2008) to 1/1000 (Solignat et al., 2009) that was
associated with the La Reunion outbreak. CHIKV can rapidly spread
through naïve populations, which has been shown with the La Reunion
outbreak and recent spread through the Caribbean (Lum and Ng, 2015).
With no vaccine and no licensed treatment there is a great need to conduct

2

research on CHIKV to increase our understanding of this disease and
identify ways to prevent or treat infections.
The purpose of this research was to develop an animal model capable
of replicating symptoms of CHIK in humans, which we accomplished by
infecting DBA1/J mice in the footpad to induce joint swelling, myositis and
tenosynovitis (Dagley et al., 2014). We have also shown the utility of this
model by testing 4 different compounds (mDEF201, GP1681, methotrexate
and anti-IL6), which show varying results from protection to exacerbation.
With CHIK observed more frequently in the United States, it has
become an important focus for research, but sadly we are lacking a lot of
information on natural infection, including the interplay between virus and
host immunological processes during CHIK. The mechanisms underlying
severe disease are poorly understood. This is especially important in regard
to immune therapy. We hypothesize that modifying the immune response
will ameliorate disease in CHIKV infected mice by limiting the immunemediated pathology. We tested this hypothesis with several different
strategies and the results of our studies demonstrate the complexities
associated with immunomodulatory strategies.
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2. LITERATURE REVIEW
2.1 Overview of Chikungunya and associated symptoms
CHIKV is an alphavirus that was first identified in Africa in the 1950s
where it was given its name that in Makonde means “that which bends up ”
(Ross, 1956). This virus has been identified in 80 countries across 5
continents and caused more than 6 million cases of human disease
(Petitdemange et al., 2015). CHIKV has led to several outbreaks in Africa
and Asia and has affected more than 3 million people in the Indian ocean
zone, and led to the establishment of autochthonous disease cases in Europe
during the 2005-2007 outbreak (Hoarau et al., 2010). In 2005-2006, 266,000
cases (1/3rd of the population) were reported in La Reunion Island. This
outbreak was unprecedented as many of the cases exhibited atypical
manifestations, including severe complications in adults (persistent
arthralgia, arthritis, and neurological complications), encephalitis in
newborns and increasing human morbidity (Hoarau et al., 2013). CHIK
fever has also been documented in many areas including France, Italy,
Australia and the USA, where international travelers have facilitated the
introduction of the virus from endemic areas (Mahendradas et al., 2013).
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CHIKV is spread to humans by the bite of an infected mosquito. The
typical vector is Aedes aegypti, but in 2006 a mutation in the E1 envelope
gene allowed more efficient transmission of the virus by Aedes albopictus, a
mosquito species that has a wide distribution throughout the world,
including the United States (Sourisseau et al., 2007). This mutation is
postulated to have facilitated the replication and transmission of the virus in
mosquitoes by reducing the cholesterol dependence of the virus
(Mahendradas et al., 2013). This vector also associates in more peridomestic
locations, which can allow the virus to cycle from human to mosquito to
human due to high viremia (10^7 pfu/ml average) in infected individuals
(Thiberville et al., 2013).
The Alphaviruses are divided into two groups; one that causes arthritis
(CHIKV, Semliki Forest virus, O’Nyong Nyong virus, Ross River virus and
Barmah Forest virus) and another that causes encephalitis (western, eastern,
and Venezuelan equine encephalitis viruses) (Leung et al., 2011). These are
enveloped, positive-sense, single-stranded RNA viruses that are
approximately 12 kb in length. The genome of CHIKV codes for capsid
protein (CP), 2 surface envelope glycoproteins (E1 and E2), 2 small peptides
(E3 and 6k) and 4 nonstructural proteins (nsP 1-4) (Voss et al., 2010). The
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CP is multifunctional and plays a crucial role in the assembly and budding
phase (Goh et al., 2015). The replication cycle begins with the attachment of
E1 to unknown cellular receptors, which leads to fusion of the viral particle
to the host cell membrane. After virus entry, the positive-sense genomic
RNA acts directly as a messenger RNA to produce nonstructural proteins,
which synthesize the structural proteins required for viral encapsidation and
budding (Gasque et al., 2015).
This viral infection is typically self-limiting and disease
manifestations generally include fever, swollen joints/joint pain and rash.
Arthralgia is reported in 87-98% of cases (Thiberville et al., 2013) but can
progress to a debilitating chronic arthritis, similar to RA. Typically, joint
pain is found in the ankles, wrists and phalanges (Simon et al., 2007). The
incidence of arthritis accompanying CHIK can be devastating. For example,
eighteen months after the 2006 outbreak in La Reunion, 60% of persons
infected were still reporting joint pain (Gerardin et al., 2012). CHIK is
endemic in many underprivileged and/or rural parts of Africa and India,
which have documented a significant economic burden due to this disease
(Gerardin et al., 2012). This study also emphasizes the importance of
controlling the perinatal mother-to-child spread of virus infection, which can
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lead to severe disease in infants born to infected mothers, including
developmental delays or encephalopathy (Gerardin et al., 2014). Severe
cases of CHIK may include neurologic or hepatic manifestations
(Schuffenecker et al., 2006), and occur more often in immune compromised
individuals (Das et al., 2010). Since late 2013, CHIKV has reached the
shores of the Americas, causing more than a million cases of infection (Lum
and Ng, 2015). Mosquito sampling conducted in Southern Mexico in 2014
yielded 32.3/1,000 mosquitos positive for CHIKV; an accompanying lack of
herd immunity and poor vector control in various parts of the Americas will
only lead to an increased spread throughout this area (Diaz-Gonzalez et al.,
2015). With increased tourism, and world travel, recent outbreaks of
CHIKV in Europe and the Americas make this virus one of critical research
importance, especially since there is no vaccine and only supportive therapy
for treatment.
2.2 Immune response to Chikungunya
The bodies’ innate immune response to CHIKV includes type-1
interferon (IFN) signaling through its receptor (IFN-I-R), which is present
on most cells including natural killer (NK) cells. IFN has a strong anti-viral
activity and activation of this protein through various pathways is the
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primary response to virus infection. The interferon response promotes the
transcription of genes for various antiviral proteins. These proteins interrupt
steps in the viral life cycle, including virus penetration, and uncoating,
transcription of viral mRNAs, synthesis of viral proteins, replication of viral
genome, and assembly and release of progeny (Sen, 2001).
IFN works by activating the Janus kinase-signal transducers and
activators of transcription (JAK-STAT) pathways, stimulating production of
IFN-stimulated genes (ISGs) of which there are 100s, that help establish a
cellular antiviral state (Ivashkiv and Donlin, 2014). Regulation of this
system is complex and often stochastic in that not all infected cells produce
Type-1 IFN or express ISGs (Ivashkiv and Donlin, 2014). Type-1 IFNs also
play a pivotal role during chronic infections, mediating the production, and
function of inflammatory cytokines and suppressing the production of
pathogenic cell types. This immunosuppressive state is thought to limit host
toxicity, and morbidity during chronic infections, allowing for coexistence
of host and pathogen (Ivashkiv and Donlin, 2014).
NK cells respond to infection with the help of cytokines, including
interleukin (IL)-12 and IL-18, which then results in the killing of infected
cells. NK cells mediate their antiviral effects through at least three different
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mechanisms: (1) the release of immunoregulatory cytokines, particularly
IFN-γ which enhance the innate immune response and help to shape the
subsequent adaptive immune response, (2) the production of cytolytic
granules for lysis of infected cells, and (3) the induction of target-cell death
through cell surface receptors (Petitdemange et al., 2015). In CHIKV
infection NK cells do not produce as much IFN-γ as they do with other
infections, which is due to an immune evasion mechanism of the virus
linked to modulation of CD56bright NK-cell subset (Petitdemange et al.,
2015).
When infection by a pathogen is detected by antigen presenting cells,
they secrete IL-12 and IL-18 that in turn stimulates the production of IFN-γ,
a type II IFN (Schroder et al., 2004). IFN- γ also works through the
JAK/STAT pathway. The C57BL/6 mouse strain produces a significantly
higher amount of IFN- γ as compared with the commonly used BALB/c
strain, leading to a greater resistance to bacteria and viruses in C57BL/6
mice (Schroder et al., 2004). IFN- γ induces a specific feedback inhibitor of
itself, the suppression of cytokine signaling (SOCS)-1 protein, which
associates with JAK to interfere with tyrosine kinase activity, and inhibiting
further downstream stimulation of IFN-γ production (Schroder et al., 2004).
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Although NK cells are typically beneficial in the acute phase of
infection, they can also be harmful by maintaining an inflammatory
environment (Long and Heise, 2015). Reduced joint pathology is also
associated with limited NK cell activity (Teo et al., 2015). One of CHIKV’s
nonstructural proteins can also inhibit transcription in vertebrate cells,
although the mechanism for this is unknown (Akhrymuk et al., 2012).
Another immune evasion mechanism is a targeted block of late synthesis of
antiviral mRNA transcripts, which are strongly induced by CHIKV and
accumulate but are not synthesized into proteins, this is thought to occur
through blocking global cellular protein synthesis (White et al., 2011).
Monocytes are one of the main producers of IFN-α, and concentrations of
IFN-α generally correlate with plasmatic viral load (Petitdemange et al.,
2015), further underscoring the importance of a strong innate immune
response, including IFN, in the control of acute CHIKV infection. People
with an attenuated innate response, such as pregnant women, the very
young, and very old, are more susceptible to CHIKV infection (Wauquier et
al., 2011).
Monocytes, and macrophages have been suggested to be a cellular
vehicle for virus dissemination as well as being a reservoir for persistent
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CHIKV infection (Hoarau et al., 2010; Labadie et al., 2010). IFN-γ and IL12 act synergistically to promote innate immune cell activation and both are
increased in the majority of CHIKV patients (Ng et al., 2009). Since CHIKV
can infect these cells, stimulation of their production results in an increased
amount of susceptible cells that can increase viral titers, and enhance
dissemination.
Elevated cytokines and growth factors are observed in humans and
animal models infected with CHIKV. Growth factors are usually produced
in response to injury and viral infections, such as CHIKV. Induction of
cellular damage by the virus may lead to secretion of these factors. The
increase of IL-1β, IL-6, and decrease in RANTES are associated with severe
CHIKV infection; HGF, FGF-basic, and VEGF were also produced at high
levels during infection (Ng et al., 2009). These cytokines are meant to
protect the body from infection but can also cause more damage by eliciting
an overactive immune response. There is a fine balance that must be
maintained in the body to allow for activation during infection but downregulation once the infection has passed. When this balance is not
maintained it can lead to immune dysfunction and may include
autoimmunity. A good example of this phenomenon, and a disease that
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shares many features with CHIK, is rheumatoid arthritis (RA) where the
immune response is targeted to self-proteins on bone and cartilage in
response to cytokine dysregulation. Features of RA include increase in TNF𝛼, IL-1𝛽, IL-6, and/or IL-17 (Yin et al., 2015), many of which are also
elevated during CHIKV infection. A review by Teng identified a correlation
between CHIKV load with arthralgia and an immune mediated signature
dominated by pro-inflammatory cytokines (Teng et al., 2015).
Several cases of CHIK related, RA-like illnesses have been reported
(10-20%), where the virus is observed in synovial macrophages but without
erosion of the cartilage and bone observed in autoimmune RA (Hoarau et al.,
2013). CHIK is similar to RA in that there is a common pattern of leukocyte
infiltrate, cytokine production, and complement activation (Burt et al.,
2012). Some cases of both show bony erosions, joint space narrowing, and
test positive for rheumatoid factor and/or anti-CCP (antibodies used to
diagnose RA) (Bouquillard and Combe, 2009).
2.3 Chikungunya Models of Infection
Models used for CHIK research include zebrafish, various species of
mice, and non-human primates (NHPs). The complex interactions of the
immune system with CHIKV make each model useful for studying different
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aspects of infection. Small animal models are important for initial studies to
identify options for therapeutic intervention.
A zebrafish animal model has been developed and used to visualize
CHIKV infection and innate host response to infection (Palha et al., 2013).
Fish are a useful research model because they are easy to manage and have
an innate and adaptive immune response like that of mammals; but for the
first month of life larval stage, zebrafish rely solely on innate immune
responses (Langevin et al., 2013). Live imaging is also possible and easily
done in fish. The antiviral compound, Suramin, was tested in fish and was
shown to have some activity against CHIKV through binding to the E1/E2
glycoprotein to block viral entry and transmission (Ho et al., 2015).
Mice deficient in interferon receptors (i.e., AG129 or A129 mice)
develop rapid mortality due to a lack of type 1 interferon signaling during
infection (Couderc et al., 2008). Susceptibility to CHIKV is also age
dependent in mice, suckling mice at 6 days old succumb to viral infection
because they are lacking an adequate immune response mechanisms while at
9 days 50% survive infection (Couderc et al., 2008). Adult mice generally
survive CHIKV infection. These models emphasize the importance of the
interferon response and a developed immune response to resilience to CHIK
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and give insight into tissue and cell tropism of the virus. Fibroblasts have
been identified as the main cell type targeted by CHIKV in mice (Couderc et
al., 2008).
In 2010 Gardner et al. found that young C57BL/6j mice were
susceptible to CHIKV infection when infected in the footpad. This model
produces measurable footpad swelling, myositis, and tenosynovitis (Gardner
et al., 2010). Mice are by no means a perfect model for studying human viral
infections and differ substantially in some mechanisms of pathogenesis and
immune response, which may limit in some way their predictive value for
pharmaceutical studies (Louz et al., 2013).
Recently Seymour et al. (2015) developed a persistent infection model
to mimic chronic infection often seen in humans. Footpad measurements,
viremia, viral load in tissues, and histological findings are used as
parameters. This model is suitable for testing vaccines. It is in recombinant
activating gene 1 (RAG1-/-) knockout mice, deficient in both T and B
lymphocytes, and models infection of the immune compromised populations
in CHIKV-endemic countries with a high prevalence of HIV and
undernourishment. This model was used to demonstrate the occurrence of
tissue damage in the absence of an adaptive immune response and to study
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vaccine safety. Since this model is in immune-compromised mice, it has
limited applicability in other studies with CHIKV where immune
competence is important (Seymour et al., 2015).
In our research, we have found the DBA/1J mouse strain to have
utility in preclinical testing of therapies that target both viral replication and
the associated joint disease (Dagley et al., 2014). Infection of DBA/1J mice
via subcutaneous injection into the footpad results in the development of
high viral titers, joint swelling, and muscle degeneration. This model works
with different strains of CHIKV including S27 (African strain) and LR2006
OPY1 (La Reunion 2006 emergent strain). Differential response of this
mouse strain to different virus strains has been demonstrated and the S27
strain of the virus required approximately 1,000-fold higher titers in order to
induce a similar disease as compared with the LR2006 OPY1 strain. Details
on the development and use of this model are included in the following
chapter.
A hamster model was recently developed that produces consistent
infections showing high viral titer, inflammatory lesions involving skeletal
muscle, fascia, and tendon sheaths of multiple limbs following subcutaneous
infection (Bosco-Lauth et al., 2015). Hamsters make excellent models for
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other arboviruses including West Nile virus (WNV) and Japanese
Encephalitis virus (JEV) (Bosco-Lauth et al., 2011), because they are
outbred, easily managed when compared to some models, and have an intact
immune system.
CHIKV is maintained in a sylvatic infection cycle within populations
of non-human primates (NHPs) and NHPs are routinely used as sentinels to
alert health departments of the presence of CHIKV. NHPs have been used to
model persistent infection as well and infected macrophages were found to
remain in the liver and lymph nodes up to 6 months following infection
(Labadie et al., 2010). Primate models are important in identifying and
characterizing therapeutic or prophylactic strategies to treat CHIK infection
prior to clinical trials in people (Labadie et al., 2010). NHPs have an intact
immune system and mimic many of the viral, clinical, and pathological
infection seen in humans, making them necessary in preclinical evaluation of
vaccines and therapeutics, as well as for the discovery of mechanisms of
CHIKV pathogenesis (Broeckel et al., 2015).
With all the animal models (Table 2-1) available, we are still severely
lacking many important aspects of CHIKV pathogenesis, and most
importantly there is no treatment and no vaccine available.
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Strain

Utility
Visualize CHIKV infection,
innate host response to
infection, Suramin testing
Inefficient IFN
signaling increases
susceptibility
Antiviral and vaccine testing

Symptoms similar to humans

Pathogenesis of viral infection in
highly susceptible
immunocompromised populations

Easily managed, cost effective

PRO

Differ from humans in
pathogenesis and immune
response

Immunocompromised

Far removed from humans

CON

Expensive, few facilities available to
manage BSL-3 conditions

Lacking some human aspects of
disease

Immunocompromised

Differ from humans in
pathogenesis and immune
response

Demonstrates chronic infection,
many joints affected by viral
inoculation

Persistent infection
Intact immune system, model
used in other alphavirus testing,
outbred model

Consistent infection, high
systemic viral titers, easily
managed

Table 2-1
Summary of CHIKV animal models, including utility, pros and cons of each discussed.
Animal
Zebrafish

AG129

C57BL/6

Mouse

Mouse

Study innate immune response

DBA/1J
RAG -/-

Antiviral and vaccine
testing, pathogenesis of
CHIKV

Mouse
Mouse
Golden
Syrian

CHIKV pathogenesis,
antiviral and vaccine preclinical testing

Antiviral and vaccine
testing, mDEF201
testing

Hamster

Rhesus
Macaque

Nonhuman
Primate
(NHP)
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3. PROTECTION AGAINST CHIKUNGUNYA VIRUS INDUCED
ARTHRALGIA FOLLOWING PROPHYLACTIC TREATMENT
WITH ADENOVIRUS VECTORED INTERFERON (MDEF201)1

3.1 Abstract

Recent outbreaks of Chikungunya virus (CHIKV) infection have
resulted in millions of cases of disease with significant morbidity. No
approved antiviral treatments exist for the prevention or treatment of this
viral disease. Infection with CHIKV results in a high rate of symptomatic
disease that primarily includes a debilitating arthralgia. To model this
cardinal disease manifestation, adult DBA/1J mice were challenged with
CHIKV by footpad injection. Viremia and hind limb virus titers increased
~100-fold while spleen virus increased >1,000-fold within 1 day post-virus
infection (dpi). Footpad swelling was measured over a 10-day period, with
peak swelling observed between 6 and 7 dpi. Histology of the hind leg at the
site-of-virus challenge showed evidence of myositis and synovitis starting on
5 dpi. Cytokine profiling of the hind limb at the site of inoculation revealed a
biphasic inflammatory response represented by an increase in IL-6, MCP-1,

Coauthored by Jane Ennis, Jeffrey D. Turner, Kerry A. Rood, Arnaud J. Van Wettere,
Brian B. Gowen and Justin G. Julander
1

25

IFN-γ, MIP-1α, RANTES, and IL-17. To investigate the prophylactic
capacity of IFN, mice were treated with mDEF201, an adenovirus-vectored
IFN-α. Intranasal administration of a single 107 pfu/ml dose of mDEF201
administered 21 days to 24 h prior to infection, significantly reduced footpad
swelling, virus titers in the hind leg and spleen, and several inflammatory
cytokines. Efficacy was not observed when treatment was initiated 24 h after
virus challenge. This arthralgia model of CHIKV recapitulates relevant
disease features commonly observed in human disease making it applicable
to preclinical testing of therapies that target both viral replication and the
associated joint disease.
3.2 Introduction
CHIKV virus (CHIKV) is associated with significant morbidity and
mortality worldwide. Historically, the primary vector for spread of CHIKV
was Aedes aegypti, although recent adaptive mutations within the virus have
resulted in a more efficient infection of Aedes albopictus (Tsetsarkin et al.,
2006). This has resulted in outbreaks outside the historical range, making
this emerging virus a major public health concern.
The rapid emergence of CHIKV and the millions of cases of disease
underscore the importance of the development of countermeasures to
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prevent or treat the symptoms of CHIKV. Fever and arthralgia are common
symptoms of CHIKV infection, although a small number (5-18%) of
infected people, especially those below age 25, are asymptomatic (DupuisMaguiraga et al., 2012). Mortality as a result of CHIKV infection is rare and
is generally associated with underlying health issues (Thiberville et al.,
2013). Rheumatic manifestations typically affect the extremities, primarily
including ankles, wrists and phalanges (Kennedy et al., 1980). A study
conducted after the La Reunion Island outbreak identified persistent arthritis
in over half of the participants 15 months after acute infection, with 43% of
those with persistent arthritis significantly impaired in carrying out daily or
household activities (Sissoko et al., 2009). As the rheumatic disease is
debilitating and very common in persons infected with CHIKV, it would be
important to prevent or treat this aspect of the disease.
An animal model that replicates human arthralgia is essential for the
development of countermeasures for the prevention and treatment of disease
associated with CHIKV infection. Macaques have been used to study
CHIKV, and this model mimics many acute symptoms seen in humans such
as fever, rash, and high viral titers but displays inconsistent swelling of the
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joints and lacks the joint and muscle pathology typically observed after
infection with CHIKV (Higgs and Ziegler, 2010).
Various mouse models have been developed which model different
aspects of the disease. The C57BL/6 neonatal mouse model includes
relevant disease manifestations such as joint swelling. There is also
consistency between disease seen in children less than one year of age and
this model, with virus being found in similar organs and a strong agedependent correlation with severity of disease (Couderc et al., 2008).
Interferon receptor knockout mice were highly susceptible to infection with
CHIKV and rapidly succumbed to infection (Couderc et al., 2008), which
serves to model severe infection and mortality that is occasionally seen.
Infection of these immunocompromised mice results in dissemination of the
virus to all tissue types, including the central nervous system (Partidos et al.,
2011). This pathology may have relevance in light of recently reported
neurologic complications of encephalopathy in newborns and meningitis and
encephalitis in older children and adults (Arpino et al., 2009). Inoculation of
the footpad of 14-day old C57BL/6 mice resulted in swelling, arthritis,
tenosynovitis, and myositis (Morrison et al., 2011), but a neonatal model has
limitations, especially in regard to testing vaccines. Others have developed a
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model of footpad swelling and joint involvement in adult C57BL/6 by
injecting virus into the footpad (Gardner et al., 2010).
A replication-deficient adenovirus type 5 vector containing a gene for
mouse IFN-α, mDEF201, is administered intranasally where it enters nasal
epithelial cells and expresses the transgene (Julander et al., 2011). This
results in the production of systemic levels of IFN several hours after
treatment (Wu et al., 2007). With non-lethal infections such as CHIKV, type
I interferon (IFN) plays a role in coordinating early antiviral immune
response (Havenar-Daughton et al., 2006), and plays a central role in
controlling CHIKV infection, acting indirectly as an antiviral through the
induction of IFN-stimulated genes that inhibit viral replication (Schilte et al.,
2010). The nonstructural proteins (nsPs) of CHIKV antagonize the IFN
response as infection progresses, so the timing of IFN intervention is critical
(Fros et al., 2010).
This manuscript details the establishment of an adult mouse model of
CHIKV arthritis and swelling. Footpad swelling, virus replication, and
cytokine profiles are used as parameters for the characterization of the
antiviral effect of mDEF201 against CHIKV. These results demonstrate the
utility of this model for use in antiviral studies.
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3.3 Materials and Methods
3.3.1 Cells
C6/36 cells were obtained from ATCC (Manassas, VA) and were used
for virus propagation. These cells were grown in RPMI at 28˚C with 5%
fetal bovine serum (FBS). Vero 76 cells, maintained in minimal essential
medium (MEM) supplemented with 10% FBS, were also obtained from
ATCC and were used in viral titer assays. Media was obtained from Hyclone
Laboratories, Logan, UT.
3.3.2 Virus
CHIKV strain S27 (VR-64) was obtained from ATCC. Stock virus
was prepared by harvesting supernatant from C6/36 cells 2 days after
inoculation.
3.3.3 Animals.
Seven-week old DBA/1J mice were obtained from Jackson
Laboratory. Mice were quarantined for 48 hours prior to infection.
3.3.4 Test Materials
A stock of mDEF201 was provided by Defyrus (Toronto, ON,
Canada), which had a titer of 1.45 X 109 pfu/ml (construction of vector
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described fully in Wu et al, 2007). An empty Ad-5 vector was also provided
by Defyrus, which was used as a negative control.
3.3.5 Experimental Design
For model characterization studies, DBA/1J mice were randomly
assigned to groups of 10 animals. Mice were challenged under isoflorane
anesthesia by footpad and hock injection with 108 CCID50/0.1 ml of virus
(0.05 ml at each site) diluted in MEM. On days 1-10, 14, and 21, 4 mice
were necropsied and serum, hind legs, and spleen were collected, weighed
and prepared for virus titration, and cytokine profiling. Animals were also
weighed throughout the study to determine the effect of infection on weight
change.
For treatment studies, mice were randomly distributed into groups of
10 to 15 animals and were treated with mDEF201, empty vector or saline.
Sham infected controls were also included to monitor potential toxicity of
treatment. In the first study, animals were treated with a range of mDEF201
doses. At 2 dpi, 5 animals per group were necropsied and spleens and hind
limbs were harvested, weighed, and the virus titer was determined. Virus
titer and cytokine levels were determined from hind limb homogenates. The
remaining animals were weighed on days 0, 2, 4, 6, 8, & 10. The
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dorsoventral thickness of the footpad at the site of virus challenge was
measured with a digital caliper and the percent increase, as compared to the
contralateral foot, was calculated.
In subsequent studies, a dose of 107 of mDEF201 was administered
intranasally at various times prior to or after virus challenge to determine the
effect of extended prophylaxis or therapeutic treatment on CHIKV infection.
Footpad increase in all animals was measured on 6 dpi as described above.
Tissues were then harvested from a subset of animals on 6 dpi with virus and
cytokine titers determined as described below.
3.3.6 Tissue virus titer determination
Samples were homogenized and diluted in 1 ml MEM, containing
0.05 mg/ml gentamicin. The homogenate was centrifuged for 10 min at 2300
RCF added to Vero 76 cells in triplicate and examined for cytopathic effect
(CPE) on 3 dpi. Virus titers were determined by end point titration as
described previously (Reed and Muench, 1938).
3.3.7 Cytokine analysis
Homogenized leg samples were evaluated for proinflammatory
cytokine/chemokine levels using the Quansys Q-plexTM Mouse Cytokine
Array (Quansys Biosciences, Logan, UT). The Quansys array quantifies
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levels of murine IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL12p70,
IL-17, MCP-1, IFNγ, TNFα, MIP-1α, GMCSF and RANTES. Samples were
diluted in sample diluent at 1:5 and 1:20 concentrations. A standard curve
for each antigen was generated by serial dilution of antigen standards from
1:3 to 1:729. Standards were plated in duplicate on opposite sides of the
plate and samples were plated at two dilutions. Manufacture’s instructions
were followed for adding substrate, incubating and washing. Plates were
quantified on a Quansys Q-View TM Imager with Q-View TM software.
3.3.8 Histopathology
Right and left hind legs were collected at 6 and 12 h, and days 1-10,
14 and 21 post-infection. Samples were fixed in 10% formalin and sent for
analysis to the Utah State University Veterinary Diagnostic Laboratory.
Samples were paraffin-embedded and sectioned for histopathologic
evaluation. Slides were stained with hematoxylin and eosin.
3.3.9 Statistical analysis
Statistical analyses were done using one-way ANOVA using a
Bonferroni group comparison (Prism 5, GraphPad Software, Inc).
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3.4 Results
3.4.1 Characterization of CHIKV infection of DBA/1 mice
Several mouse strains, including C57BL/6, AG129, CAST/EiJ and
DBA/1J, were inoculated with CHIKV and disease signs, including footpad
swelling, differences in behavior, weight change and mortality, were
observed. The DBA/1J strain was selected based on the development of
robust footpad swelling, availability and use in arthritis research (Chiba et
al., 2012, Eros et al., 2009 and Nishida et al., 2002). To characterize CHIKV
replication and disease in this mouse strain, DBA/1J mice were inoculated
with S27 CHIKV in the rear hind footpad and footpad swelling, virus titer of
various tissues, cytokine levels, and weight change were quantified.
Significant swelling of the footpad, ankle and hock at the site of virus
challenge was observed as early as 6 dpi (Fig. 1A). The contralateral footpad
was normal and served as a control for measuring percent increase in
footpad thickness. Swelling was time-dependent and showed a dose
responsive increase depending on virus challenge dose (data not shown).
Significant swelling (P < 0.001) of the footpad was initially observed on
6 dpi, with peak swelling on 7 dpi. Footpad thickness returned to baseline
levels by 9 dpi. Average virus titer in the right hind leg at the site of
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inoculation was approximately 6 log10 CCID50/g at 6 h after virus challenge
(Fig. 1B), which was due to the footpad inoculation at this site. Titers
increased approximately 100-fold to just below 8 log10 CCID50/g at 24 h
after virus challenge. The right hind leg virus titers persisted at an average
titer of 6–7 log10 CCID50/g until 6 dpi, at which point they began to return to
baseline levels and were below the limit of detection on 8 dpi. In contrast, no
virus was observed in the left hind leg contralateral to the injection site.
Virus titer in the spleen was detected as early as 12 h after virus
challenge. Spleen titers peaked at around 7 log10 CCID50/g tissue, which was
>1000-fold increase in virus above the level of detection in that organ (Fig.
1B). Virus was reduced below the limits of detection by 4 dpi. A similar
increase in serum virus was also observed, although a more rapid clearance
of viremia was observed with virus titer reduction to undetectable levels a
day earlier on 3 dpi as compared with spleen titers (Fig. 1B). No virus was
detected in any of the tissues assayed from sham-infected animals (data not
shown).
Splenomegaly was observed in mice infected with CHIKV as early as
2 dpi, with spleen size continuing to increase through 10 dpi (Fig. 1C).
Weight change of CHIKV-infected mice did not differ significantly from
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that of sham-infected animals (data not shown).
Histologic analysis of the right hind limbs demonstrated cellulitis,
myositis, tendinitis, and teno and arthrosynovitis as early as 5 dpi, which
continued over the course of the infection (Fig. 2). No significant
histological lesions were seen on the left hind limb (Fig. 2A and C). Several
proinflammatory cytokines were significantly elevated in tissue homogenate
of the limb inoculated with CHIKV. There appeared to be a biphasic
increase in cytokine levels in the hind leg with an initial peak in IL-6, MCP1, IFN-γ, MIP-1α, RANTES, and IL-17 around 1 dpi with a subsequent peak
in levels 5–7 dpi (Fig. 3). Other cytokines, including IL-1α, IL-1β, IL-2, IL3, IL-5, IL-10, IL-12, TNF-α, and GM-CSF did not appear to be affected by
CHIKV infection of mice as compared with control mice (data not shown).
Cytokine levels in the serum of infected animals were not significantly
altered after CHIKV infection (data not shown). There did appear to be some
slight increase in serum IL-6, MCP-1, MIP-1α, and RANTES on 2 dpi,
which corresponded with the initial peak observed in the hind limb at the site
of virus inoculation, but the second peak around 8 dpi was only observed
with IL-6 and MCP-1 (Table 1), suggesting a more localized effect at the
site of inoculation. Cytokine titers in the spleen were similar to those in the
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serum, with the exception of RANTES levels that were elevated 20–87-fold
in the spleen homogenates as compared with serum on 2 and 9 dpi (Table 1).
Sham-infected animals also had higher levels of RANTES in the spleen as
compared with serum, suggesting higher baseline levels in this tissue.
3.4.2 Treatment of CHIKV with mDEF201
To determine the effect of mDEF201 treatment on the development of
disease after CHIKV infection, animals were treated with a single intranasal
instillation 24 h prior to virus challenge. Evaluation parameters used to
determine mDEF201 efficacy included percent footpad swelling as
compared with the contralateral foot, virus titers in the hind leg and spleen
and cytokine levels in the hind leg.
Footpad swelling was significantly (P < 0.001) reduced on 7 dpi in
animals treated with 107 pfu/ml of mDEF201 as compared with placebo- and
empty vector-treated controls and was comparable with sham-infected
controls ( Fig. 4A). A significant (P < 0.001) reduction of viral load was
observed on 2 dpi in hind limbs and spleens of animals treated with
107 pfu/ml of mDEF201 as compared with placebo- or empty vector-treated
animals (Fig. 4B and C, respectively). Average titers in these tissues were
reduced approximately 2 log10 CCID50/g.

37

Fig. 3-1. Disease parameters of mice infected with the S27 strain of CHIKV.
(A) The effect of CHIKV infection on the time course of footpad swelling of
DBA/1J mice at the site of virus challenge when compared to contralateral
footpad. (B) Time-course of virus in serum, spleen, right hind leg, and left
hind leg of DBA/1J mice infected with CHIKV. Viral titer is plotted as 50%
cell culture infectious dose (CCID50) per gram of tissue or ml of serum.
Upper dashed line is the average limit of detection for tissue homogenates
and lower line is for serum. (C) Comparison of Sham infected and CHIKV
infected spleen weights in grams throughout course of infection
(∗∗∗P < 0.001, ∗P < 0.05, as compared with sham-infected controls).
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Fig. 3-2. Hematoxylin and eosin stained sections of skeletal muscle (A and
B) and footpads (C and D) show pathologic changes after CHIKV infection.
(A) Normal skeletal muscle taken 5 dpi from control mice. (B) Myositis
(arrow head) and tendinitis (arrow) are apparent in the skeletal muscle of a
CHIKV-infection mouse taken on 5 dpi (400× magnification of skeletal
muscle, bar = 50 μm). (C) Normal footpad section from a mouse on 7 days
after mock infection. (D) Cellulitis due to mixed inflammatory cell
infiltration is observed on 7 dpi in footpad sections taken 7 dpi from mice
challenged with CHIKV (200× magnification of footpad sections,
bar = 200 μm).
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Challenge IL-6
CHIKV
6.6 ± 9.4a
Sham
bdlb

107 ± 41
26

RANTES
50 ± 20
31 ± 0.8

9 dpi
IL-6
10.4
bdlb

20 ± 9.1 669 ± 7.7
23
1959

MCP-1
MIP-1a RANTES
383 ± 503 14 ± 0.8 35 ± 1.8
26 ± 0.4
16 ± 4.4 34 ± 1.1
219 ± 181 4351 ± 661 9.9 ± 1.6 29 ± 4.3
28
1056
bdlb
26

MCP-1
MIP-1a
223 ± 147 10 ± 0.8
25
9.9 ± 2.0

Table 3-1
Serum and spleen levels (pg/ml) of selected cytokines of DBA/1J mice challenged with CHIKV. Virus challenge did
not appear to cause an increase in cytokines in these tissues as compared with cytokine levels at the site of virus
challenge.

Tissue
Serum

2 dpi

Spleen

bdlb
bdlb

CHIKV
Sham

a Mean ± standard deviation for 2 samples is shown. Values with no SD listed are from single data points.
b Below detection limit
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Footpad swelling and tissue titers in groups treated with lower doses
of mDEF201 were similar to those parameters of saline- or empty vectortreated controls and had no observed effect on disease (Fig. 4A–C).
Reduced levels of key cytokines, including IL-6, MCP-1, MIP-1α, and
RANTES, were observed on 2 dpi in the virus-inoculated hind limb of mice
treated with the highest dose of mDEF201 as compared with saline treatment
(Fig. 4D–G, respectively). These reductions were significant (P < 0.05) for
MCP-1 and RANTES (Fig. 4E and G, respectively). In a subsequent study,
cytokine levels from hind leg samples taken 6 dpi from animals treated with
107 mDEF201 or with saline were quantified and showed a similar trend
towards reduction of IL-6, MCP-1, and MIP-1α (Fig. 4H–J, respectively), as
well as a significant (P < 0.001) reduction in RANTES (Fig. 4K).
To determine the effect of treatment with mDEF201 after virus
challenge, 107 pfu was administered 24, 48 or 72 h post-inoculation.
Administration of mDEF201 at these time points failed to significantly
impact footpad thickness, virus titer or reduction of cytokine levels in the
hind limb (data not shown). As a positive control to this study, mDEF201
was administered at 24 h prior to virus challenge, which reduced footpad
thickness as in previous studies. Virus titers measured in hind limb samples
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taken on 6 dpi, however, were not significantly reduced (data not shown),
despite a previously observed reduction of virus titer on 2 dpi after treatment
with DEF201 given along the same schedule (Fig. 4B).
Extended prophylaxis evaluation was conducted to test the efficacy of
mDEF201 when administered as early as 21 days prior to infection. Swelling
of the footpad was significantly reduced (P-value <0.001) in animals treated
one day prior to virus challenge (Fig. 5A), as seen in previous studies. A
single treatment with mDEF201 on 7, 14, or 21 days prior to virus challenge
prevented footpad swelling at the site of virus inoculation (right hind leg).
Treatment at these time points resulted in footpad thickness similar that
observed for sham-infected, treated controls, and were significantly
(P < 0.001) lower than that of infected animals treated with empty vector or
with placebo (Fig. 5A).
Treatment of mice with mDEF201 1 or 7 days prior to virus challenge
had no effect on reducing virus replication in the hind leg (at the site of virus
challenge) as measured on 6 dpi (Fig. 5B). However, mice that were treated
14 or 21 days prior to virus challenge had significantly lower (P < 0.01)
virus titers than animals treated with empty vector or placebo.
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Cytokine levels were measured from hind leg homogenates of the
inoculated limb (also used for virus titration), which were taken from a
subset of animals on 6 dpi. In general, treatment with mDEF201 at all time
points prior to virus challenge resulted in significant reduction (P < 0.001) in
IL-6, MCP-1, MIP-1α, and RANTES when measured 6 dpi (Fig. 5C–F,
respectively). One exception was the lack of significant reduction of IL-6 in
animals treated one day prior to virus challenge (not shown), which was
consistent with previous results (Fig. 4H).
3.5 Discussion
Infection of DBA/1J mice with CHIKV mirrors several disease signs
observed in humans, including arthralgia, high acute viral titers and
increased cytokine levels (Couderc and Lecuit, 2009). This non-lethal model
focuses primarily on the arthritic disease manifestations that occur most
commonly in infected individuals. The primary clinical and economic
burden of human CHIKV disease is arthralgia, which renders infected
individuals unable to work and perform other necessary activities, which in a
setting of limited resources, can be a large drain to the financial wellbeing of
hundreds of thousands of people. Treatment or prevention of arthralgia in
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infected individuals, therefore, would be very important to reducing the
burden of this viral disease.
Increased levels of several cytokines, accompanied by swelling and
severe tissue damage, were observed in mice infected with CHIKV 6-7 dpi.
Infected patients have elevated IL-6, GM-CSF and MCP-1 during infection
(Chirathaworn et al., 2013) (Lohachanakul et al., 2012), further supporting
the relevance of this mouse model to human infection. In addition,
mDEF201 prophylactic treatment alleviated cytokine elevation and footpad
swelling. The immune response to infection, including recruitment of
macrophages by MCP-1 and activation of these cells by IL-6 within the
joint, plays an important role in the immunopathogenesis associated with
CHIKV infection and is a common mechanism of disease of various viral
arthritides (Suhrbier and Mahalingam, 2009). It is likely that the arthrogenic
immune response in CHIKV infection is excessive and may be targeted as
an immunopathology, as evidenced herein by progressive clearance of the
virus as the joint swelling and cytokine response mounts. This must be
further delineated, but future studies will focus on targeting specific aspects
of the immune response to determine the effect of immunotherapy as a
treatment for arthralgia associated with CHIKV infection.
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Fig. 3-3. The effect of mDEF201 administered intranasally 24 h prior to
virus challenge at doses of 107, 106, or 105 pfu/animal. (A) The percent
increase in footpad swelling at the site of virus challenge was significantly
reduced as compared with the contralateral footpad on 7 days post infection
(dpi) in animals treated with the highest dose of mDEF201. Virus titer of
(B) the inoculated limbs and (C) spleen of mDEF201-treated or control
mice on 2 dpi. Significant reduction in virus titer was observed at the
highest dose of mDEF201. Cytokines including (D) IL-6, (E) MCP-1, (F)
MIP-1α, (G) RANTES, all cytokines show a trend towards reduction with
mDEF201 treatment. Cytokine reduction was verified in a subsequent study
and a similar trend towards reduction of (H) IL-6, (I) MCP-1, (J) MIP-1α,
and (K) RANTES was observed in the hind limb on 6 dpi after prophylactic
treatment with 107 pfu of mDEF201.
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Fig. 3-4. The effect of prophylactic mDEF201 treatment administered i.n.
on 21, 14, 7, or 1 day prior to virus challenge at a dose of 107 pfu. (A)
Footpad swelling was significantly reduced on 6 days post infection in all
treatment groups when compared with empty vector and saline treated
control groups. (B) Virus titer in the hind limb homogenates on 6 days
post infection were reduced in earlier treatment groups and (C) IL-6, (D)
MCP-1, (E) MIP-1α and (F) RANTES were generally reduced on 6 days
post infection.
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The DBA/1J mouse model appears to be a more relevant model
compared to other CHIKV models. Infection of C57BL/6 mice with the S27
East African isolate of CHIKV was also conducted in our lab in parallel with
infection of DBA/1J mice, but no significant swelling was observed. Despite
the utility observed with the C57BL/6 model in other labs, including use in
vaccine studies (Wang et al., 2011), the DBA/1J, mice appear to be more
sensitive to infection with CHIKV. In addition to infection of DBA/1J and
C57BL/6 mice, we also challenged AG129 mice in parallel (data not
shown). Similar results, including rapid mortality, were observed as
previously reported (Partidos et al., 2011). The CAST/EiJ mouse has
previously been shown to be susceptible to infection with monkeypox, a
virus that does not cause disease in BALB/c, C57BL/6, and other commonly
used inbred strains (Americo et al., 2010). For this reason, we included
CAST/EiJ mice in our mouse strain screen to determine if they would be
suitable for modeling CHIKV disease. Significant swelling of the foot and
hock was observed at the site of virus injection after footpad inoculation,
which was similar to swelling observed in DBA/1J mice. The CAST/EiJ
mice, however, are limited in availability and were abandoned in favor of
the more readily available DBA/1J strain.

47

Neonatal mouse models of CHIKV are also commonly used.
Intradermal infection of 12-day-old mice results in morbidity and mortality
(Couderc et al., 2008), representing severe disease phenotype. Virus is
detected in the muscle, joint, skin and brain tissue of these mice, which is
similar to rare cases of encephalitic disease of patients infected with CHIKV
(Gerardin et al., 2008; Ramful et al., 2007; Robin et al., 2008). While virus
was very rarely detected in the brains of infected DBA/1J mice (data not
shown), detectable titers were observed in various tissues including joints,
spleen, and serum. Use of adult DBA/1J mice allows for virus interaction
with a developed immune system and may better model aspects of human
disease that arise as a result of immunopathogenesis, which may be different
in neonatal mice.
Another potential benefit of the DBA/1J model is the consistency of
swelling among animals. All infected mice had fairly consistent swelling, as
compared with inconsistent swelling of joints and rash observed in infected
macaques in a recent study (Chen et al., 2010). In addition, no evidence of
arthritis was observed in the macaques, as compared with histopathology
consistent with arthritis in DBA/1J mice after CHIKV infection. Notably, no
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rash is detected in these mice, despite being a common disease sign
associated with CHIKV infection in man (Schmidt-Chanasit et al., 2012).
The main limitation of CHIKV infection in DBA/1J mice is the lack
of the development of a persistent chronic arthralgia that is observed in
human patients (Jaffar-Bandjee and Gasque, 2012). Measurable swelling
was observed between 5 and 8 days after virus inoculation, while joint pain
and swelling in infected patients can be observed for weeks to months, and
may even persist for years in some individuals (Couturier et al., 2012). The
few days of swelling, however, does provide a measureable parameter of
disease that can be used to determine the effect of antiviral or host-directed
therapeutics on the amelioration of this important disease manifestation. No
animal models have been shown to develop chronic arthralgia, and the basis
for the persistence of this disease parameter in man has yet to be elucidated.
Another potential limitation of this model is the lack of mortality
associated with CHIKV infection at a relatively high virus challenge.
Despite the lack of mortality in this model, other mouse strains, such as
AG129 mice deficient in IFN receptors, may be used to further characterize
the effect of antiviral therapies against more severe disease manifestations.
A study conducted during the 2005-2006 Reunion outbreak identified 610
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atypical cases where 546 of these cases had underlying medical conditions
and 65 patients died (Economopoulou et al., 2009). This aspect of
underlying medical conditions shows the potential for CHIKV to affect
immune compromised individuals. Nevertheless, arthralgia, the primary
disease manifestation in this mouse model, is still the most prominent and
debilitating aspect overall of CHIKV disease in man and should be a focus
for the development of therapeutics.
Prophylaxis with mDEF201 may have clinical potential in endemic
areas of CHIKV disease. In the event of an outbreak of CHIKV, it would be
useful to have a single dose prophylactic agent that could provide protection
over several weeks to those at risk of infection. Future studies will be
conducted to determine the pre-exposure prophylactic window for
mDEF201 utilizing the DBA/1J model.
Studies in the DBA/1J model demonstrate a rapid course of virus
replication and clearance, suggesting a limited treatment window for
antiviral compounds targeting the lifecycle of the virus. Treatment with
DEF201 results in the production of consensus IFN and a decrease in disease
when given prior to virus challenge. These studies demonstrate prophylaxis
with a safe and effective mediator of antiviral response is effective in
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preventing or ameliorating disease as a result of CHIKV infection. In
addition, vaccine development would likely be an effective means of disease
prevention within endemic regions.
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4. IMMUNE MODULATION AND EXACERBATION IN A MOUSE
MODEL OF CHIKUNGUNYA VIRUS

4.1 Abstract
Chikungunya virus (CHIKV) has been identified in 80 countries
across 5 continents and has caused more than 6 million cases worldwide
(Petitdemange et al., 2015). This viral infection is usually self-limiting and
typically results in fever, swollen joints/joint pain and rash, but can lead to
debilitating chronic arthritis. Using a mouse model of CHIKV-induced
swelling, we tested the efficacy of three immunomodulatory compounds.
Methotrexate (MTX) significantly reduced swelling, splenomegaly, and
cytokine levels. Treatment with GP1681 significantly increased swelling.
Actemra (ACT) (Anti-IL6 receptor antibody) reduced IL-6 to baseline and
significantly reduced swelling. We also tested a combination treatment of
ACT with MTX, which had a slight additive effect on disease improvement.
As expected, these immune modulators had no effect on viral titer. These
studies demonstrate the potential for improvement or exacerbation of CHIK
disease after treatment with compounds that target host immunity.
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4.2 Introduction

CHIKV is an alphavirus, which was identified in the 1950s in Africa.
The name Chikungunya roughly translates to “that which bends up”. CHIKV
is spread by mosquitoes, typically Aedes aegypti and more recently Aedes
albopictus (Wasonga et al., 2015). The immune system plays a pivotal role
on how CHIKV will affect the body. In some cases the virus is a selflimiting disease with febrile symptoms, swollen joints and a rash but may
progress to a chronic, debilitating arthritis. There is no vaccine or licensed
treatment for this disease.
Methotrexate (MTX) is a JAK/STAT pathway inhibitor (Thomas et
al., 2015). The JAK/STAT pathway is involved in signal transduction after
cytokine release and binding to immune cells and is also important in
haematopoiesis, immunity and inflammation. Having been clinically
approved for over 35 years, it is most commonly used at low doses to treat
inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s
disease (Cronstein, 2005). Methotrexate was selected for testing because of
its potential to reduce the inflammation associated with CHIK infections; by
inhibiting the JAK/STAT pathway, the downstream effects of
hypercytokinemia could potentially be reduced.
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Antiplatelet, vasodilating Prostaglandin 2 (PGI2), causes a significant
increase in the cAMP production and can attenuate inflammation via
suppressing TNF-α, IL-1β, and IL-6 production in lungs, human monocytes,
and endothelial cells (Vicil and Erdogan, 2015). GP1681 sodium, a
chemically stable PGI2 analogue, has been shown to possess a similar
pharmacological profile to PGI2 (Vicil and Erdogan, 2015). TNF-α, IL-1β,
and IL-6 play keys roles during CHIK infection, GP1681 was chosen to see
the outcome of simultaneously suppressing all 3 during initial infection.
Tocilizumab (Actemra (ACT), RoActemra) is a humanized
monoclonal antibody that acts as an interleukin-6 receptor antagonist
(Dhillon, 2014). ACT is given to patients with RA and has shown positive
results in reducing joint swelling and associated pain. The ACT label
indicates that treatment can also be effectively administered in combination
with methotrexate. IL-6 is elevated during initial infection with CHIKV,
ACT was chosen to suppress this immune response.
The purpose of this study is to evaluate these three
immunomodulatory agents in a mouse model of CHIK. These immune
mediators were tested using a DBA/1J mouse model, which develops
splenomegaly, footpad swelling and viral titers when challenged with
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CHIKV subcutaneously in the footpad and can be used as parameters of
disease to determine efficacy of the treatments (Dagley et al., 2014). We
hypothesize that specifically targeting key mediators of host immunity that
are hyperregulated during CHIKV infection will ameliorate disease in the
absence of direct inhibition of virus.
4.3 Materials and methods
4.3.1 Cells
C6/36 cells were obtained from ATCC (Manassas, VA) and were used
for virus propagation. These cells were grown in RPMI at 28˚C with 5%
fetal bovine serum (FBS). Vero 76 cells, maintained in minimal essential
medium (MEM) supplemented with 10% FBS, were also obtained from
ATCC and were used in viral titer assays. Media was obtained from Hyclone
Laboratories, Logan, UT.
4.3.2 Virus.
The Reunion Island isolate LR2006-OPY1 (LR06) was obtained from
Robert Tesh (UTMB, WRCEVA) and propagated in C6/36 cells. The LR06
CHIKV stock has a titer of 109.5 50% cell cultures infectious doses
(CCID50)/ml.
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4.3.3 Animals
Seven-week old DBA/1J mice were obtained from Jackson
Laboratory. Mice were quarantined for at least 48 hours prior to infection.
4.3.4 Test Materials
Actemra (ACT, anti-IL-6r mAb) was purchased by the attending
veterinarian from Logan Regional Hospital (Logan, UT) as a pre-formulated
solution. Dilutions were made in sterile saline and solutions were stored at
4˚C during the experiment. GP1681, along with an inactive control, was
provided by Gemmus Pharma (San Francisco, CA) in a ready to use
formulation. Methotrexate was purchased from Sigma-Aldrich (St. Louis,
MO) as a powder and prepared in sterile saline at various doses.
4.3.5 Experimental Design
Mice were randomly assigned to groups of 10 animals. A 104.5
CCID50/0.1 ml concentration of LR06 was prepared in minimal essential
media. Animals were anesthetized with isoflurane prior to subcutaneous
(s.c.) injection in the footpad and hock with a total volume of 0.1 ml of the
diluted virus (0.05 ml in each site).
At 6 dpi, 7 animals per group were necropsied and spleens and hind limbs
were harvested, weighed, and the virus titer was determined. Virus titer and
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cytokine levels were determined from hind limb homogenates. The
remaining animals were weighed every other day until Day 14. The
dorsoventral thickness of the footpad at the site of virus challenge was
measured with a digital caliper and the percent increase as compared to the
contralateral foot was calculated.
GP1681, vehicle, and inactive GP1681 were administered bid for 10 days
beginning 4 h after virus challenge. Animals were treated via the
intraperitoneal (i.p.) route. ACT was given 4 h after virus challenge and on 4
dpi. Animals were treated via the intraperitoneal (i.p.) route. An isotype
control Ab was also administered along the same treatment schedule as a
negative control. Methotrexate was given once a day from -24 h to 6 dpi.
Animals were treated via the subcutaneous (s.c.) route. Phosphate buffered
saline (PBS) was also administered along the same treatment schedule and
was included as a negative control.
4.3.6 Tissue virus titration
Samples were homogenized and diluted in 1 ml MEM, containing
0.05 mg/ml gentamicin. The homogenate was centrifuged for 10 min at 2300
RCF 10-fold dilutions were prepared and added to Vero 76 cells in triplicate
and examined for cytopathic effect (CPE) on 3 dpi. Virus titers were
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determined by end point titration as described previously (Reed and
Muench, 1938).
4.3.7 Cytokine analysis
Homogenized leg samples were evaluated for proinflammatory
cytokine/chemokine levels using the Q-plexTM Mouse Cytokine Array
(Quansys Biosciences, Logan, UT). The Quansys array quantifies levels of
murine IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL12p70, IL-17,
MCP-1, IFNγ, TNFα, MIP-1α, GMCSF and RANTES. Samples were
diluted in sample diluent at 1:5 and 1:20 concentrations. A standard curve
for each antigen was generated by serial dilution of antigen standards from
1:3 to 1:729. Standards were plated in duplicate on opposite sides of the
plate and samples were plated at two dilutions. Manufactures instructions
were followed for adding substrate, incubating and washing. Plates were
quantified on a Quansys Q-View TM Imager with Q-View TM software.
4.3.8 Statistical analysis
Statistical analyses were done using one-way ANOVA using a
Bonferroni group comparison (Prism 5, GraphPad Software, Inc).
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4.3.9 Ethics statement
This study was conducted in accordance with the approval of the
Institutional Animal Care and Use Committee of Utah State University
under the approved protocol numbers 1526 and 2339. The work was done in
the AAALAC-accredited and PHS Animal Welfare Assurance-approved
Laboratory Animal Research Center of Utah State University.
4.4 Results

4.4.1 Methotrexate dose response
At doses of 4, 2, and 1 mg/kg/d of MTX, footpad swelling was
significantly (P<0.001) reduced as compared with placebo-treated controls
(Figure 4-1). Treatment with the lowest dose of 0.5 mg/kg/d was also
effective in significantly (P<0.05) reducing swelling, although not to the
extent of higher doses. Despite significant reduction, and although some
individual animals were reduced to baseline, infected animals treated with
MTX had measureable swelling at the site of virus inoculation between 0
and 75% as compared with the contralateral foot. There were no significant
differences in swelling between the 4, 2, and 1 mg/kg/d MTX groups (Figure
1). A significant (P<0.001) increase in virus titer was observed in groups

63

treated with 4 or 2 mg/kg/d of MTX, while lower doses caused a nonsignificant increase (Figure 4-2). A trend towards a reduction in spleen size
was also observed in animals treated with the three highest doses of MTX.
4.4.2 Effect of Actemra on CHIKV infection
A significant reduction of swelling was observed in animals treated
with ACT, at 40 mg/ml (Figure 4-3). A reduction of IL-6 to baseline levels
was observed (Figure 4-4), although as expected, viral titer was not affected
(Figure 4-5).
4.4.3 Treatment with GP1681 exacerbates disease
GP1681 treatment resulted in a significant (P<0.001) increase in
footpad swelling (Figure 4-6). Interestingly, the lower dose resulted in a
greater increase in footpad swelling, although the difference between the two
treatment groups was not significant. The highest dose of GP1681 resulted
in a significant increase in virus titer on 6 dpi at the site of virus challenge,
although no increase in titer was observed in mice treated with the lower
dose (Figure 4-7).
No significant increases or decreases were observed in key cytokines
(data not shown), although MCP-1 was increased in animals treated with
GP1681. Levels of IFN- were reduced to baseline in animals treated with
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the highest dose of GP1681, while increased levels were seen in animals
treated with the lower dose of GP1681.
4.4.4 The effect of Methotrexate and Actemra Combination
Combination of methotrexate (2 mg/kg) and ACT (20 mg/ml) reduced
the swelling to levels that were slightly lower, although not significantly so,
as compared with monotherapy treatment. Treatment did not have a
synergistic effect in reducing footpad thickness (Figure 4-8). No appreciable
swelling was observed in sham-infected toxicity controls treated with either
compound.
As expected, virus titer in the hind foot at the site of virus inoculation
was not affected by monotherapy treatment with MTX or ACT (Figure 4-9,
Table 2). There was also no significant reduction in cytokine levels observed
with combination treatment (Figure 4-10).
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Fig. 4-1. The effect of methotrexate (MTX) administered subcutaneously
starting at -1 through 6 dpi at doses of 4, 2, 1 and 0.5 mg/kg on footpad
swelling. Treatment with MTX significantly improves footpad swelling on
6 dpi in DBA/1J mice infected with CHIKV. (***P<0.001, *P<0.05, as
compared with placebo treatment)
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Fig. 4-2. The effect of methotrexate (MTX) administered subcutaneously
starting at -1 through 6 dpi at doses of 4, 2, 1 and 0.5 mg/kg on virus titer of
hind limb. Virus titer at the site of inoculation is not reduced after MTX
treatment. Higher doses of MTX result in significantly increased virus titers.
(***P<0.001, as compared with placebo treatment)
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Fig. 4-3. The effect of 40 and 20 mg/ml of ACT treated intraperitoneally at 4
hrs and 4 dpi on percent increase in footpad thickness at the site of virus
inoculation as compared with the contralateral footpad in CHIKV-infected
mice. (***P<0.001, as compared with placebo treatment)

68

Fig. 4-4. The effect of 40 and 20 mg/ml of ACT treated intraperitoneally at 4
hrs and 4 dpi on IL-6. Hind limb cytokine analysis showing reduction of IL-6
to baseline levels at 40 and 20 mg/ml.
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Fig. 4-5. The effect of 40 and 20 mg/ml of ACT administered intraperitoneally
at 4 hrs and 4 dpi on virus titer. Right Hind limb viral titers are not
significantly impacted.
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Fig. 4-6. The effect of two doses (0.2 and 0.8 mg/kg/d) of active GP1681
(aGP1681), inactive GP1681 (iGP1681), or vehicle control on percent increase
in footpad thickness at the site of virus inoculation as compared with the
contralateral footpad in CHIKV-infected mice. Mice were treated
intraperitoneally twice daily for 10 days starting at 4 hours post infection (pi).
Footpad thickness was increased at both concentrations of GP1681.
(***P<0.001, **P<0.01, as compared with PBS control).
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Fig. 4-7. The effect of GP1681 on virus titer of the hind limb at the site of virus
inoculation in CHIKV-infected mice when treated twice daily for 10 days
starting 4 hrs post infection (pi). Viral titer was significantly increased at 0.8
mg/kg/d. (***P<0.01, *P<0.05, as compared to control).
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Fig. 4-8. The effect of methotrexate (MTX) at 2 mg/kg and, Actemra (ACT) at
20 mg/ml or a combination of both on footpad thickness at the site of virus
inoculation as compared with the contralateral footpad in CHIKV-infected
mice. MTX alone and in combination with ACT significantly decreased
footpad swelling. (***P<0.001, as compared with normal control).
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Table 4-1
Efficacy of Actemra (anti IL-6 mAb, ACT) and methotrexate (MTX) alone or in combination on disease of mice infected with
CHIKV.

Duration of experiment: 21 days
Treatment route: MTX- s.c., ACT- i.p.

ACT

MTX

Treatment

2 mg/kg + 20 mg/ml

20 mg/ml, single inj. +4 h

2 mg/kg/d, qd X 7 beg. -1 dpi

Dose, schedule, route

-2.1 ± 2.8

--

--

0.4 ± 3.0

Footpad
swelling (%)a

2.3 ± 0.1

2.4 ± 0.1

--

--

2.3 ± 0.0

Log10 right leg
virus titerb

--

94.8 ± 12.7

51.5 ± 18.1***

79.7 ± 23.5

61.7 ± 13.2***

Footpad
swelling (%)a

--

5.7 ± 0.8

6.1 ± 0.3

6.1 ± 0.3

6.2 ± 0.4

Log10 rt leg
virus titerb

Animals: Female 13-17 g DBA/1J mice.
Virus: Chikungunya virus strain LR06 (LR2006-OPY1, 2C6)
Virus route: s.c. footpad inoculation

MTX + ACT

40 mg/ml, single inj. +4 h

2.7 ± 3.4

Infected, treated

Isotype cont.

NA

Toxicity controlsa

Normal control

aPercent increase in footpad at the site of inoculation as compared with the contralateral foot on 6 dpi.
bRight hind limb was removed 6 dpi to determine virus titer.
***P<0.001, as compared with respective placebo treatment.
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Fig. 4-10. The effect of monotherapy or combination therapy with MTX and
ACT on cytokine profile of the hind leg at the site of virus inoculation in
CHIKV infected mice on 6 days post infection (dpi). (***P<0.001,
**P<0.01, *P<0.05, as compared with placebo treatment)
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4.5 Discussion
Treatment with Methotrexate was effective in significantly reducing
footpad swelling as compared with placebo treatment. Virus titers, however,
were increased in a dose dependent manner, which is consistent with an
indirect mechanism for disease amelioration as well as the
immunosuppressive state induced by methotrexate (Ichikawa et al., 2013).
The effectiveness of methotrexate treatment coincides with studies
conducted on humans who experience rheumatic manifestations and were
treated with methotrexate. In one particular study 54 of 72 CHIKV-infected
patients who experienced rheumatic manifestations responded well to
methotrexate treatment (Javelle et al., 2015). During this time viral levels are
not an issue as compared with initial infection. In contrast to what we see in
CHIK, when mice are infected with Ross River Virus (RRV) and treated
with methotrexate their symptoms are exacerbated (Taylor et al., 2013),
possibly due to the suppression of the immune response and increase in viral
titers is more detrimental during RRV infection. Virus titer increases were
consistent in both virus models after methotrexate treatment.
Treatment with ACT at 20 mg/ml, in combination with MTX at 2
mg/ml, significantly improved footpad swelling, spleen weights, and
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cytokine levels in hind leg and spleen. There have been few studies
conducted looking at the use of ACT during viral infection, as the drug is
most often used to combat autoimmune disease inflammatory symptoms, but
there has been some study of the effect of ACT in the treatment of chronic
hepatitis C virus (HCV) infection (Felis-Giemza et al., 2015). Virus load
was not increased when HCV patients suffering from RA were treated with
ACT (Nagashima et al., 2012), possibly indicating the involvement of IL-6
in disease manifestation. It remains to be seen if ACT is efficacious in
ameliorating disease in people infected with CHIKV, and further study is
warranted.
GP1681 is an isomer of beraprost, it is thought that beraprost works in
a similar manner to prostaglandin I2 (prostacyclin) (PGl2) by suppressing
TNF-α, IL-1β, and IL-6 production in lungs, human monocytes, and
endothelial cells (Vicil and Erdogan, 2015). PGI2 is an important mediator of
edema and pain that accompany acute inflammation, interestingly PGI2 is
the most abundant prostanoid found in synovial fluid in human arthritic knee
joints (Ricciotti and FitzGerald, 2011). However, TNF-α, IL-1β and IL-6
are key players in CHIKV infection with IL-6 increasing during the acute
phase of infection and TNF-α, and IL-1β increasing during disease
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progression when patients began to recover from acute illness (Kelvin et al.,
2011). We can assume that when all 3 of these key player cytokines are
suppressed, disease symptoms are exacerbated.
These studies provide a proof of principle that treatment of CHIK
with immune modulators may ameliorate or exacerbate disease, shows the
complexities of the immune system and that variability exists between the
responses of different alphaviruses to immune modulatory therapy.
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5. SUMMARY

CHIK is a complex viral disease that is becoming a major health
concern to people in the USA and throughout the world. The work being
done with CHIKV is greatly expanding our knowledge of this virus but as of
yet has not produced an FDA-approved vaccine or treatment. To facilitate
the discovery of novel antiviral preventative and therapeutic options, we
have developed a model that can be used in CHIK research, including testing
antivirals, vaccines and other intervention strategies. With relevant features
of footpad swelling and inflammatory cytokine involvement, preliminary
research can be conducted that can direct further clinical development in
higher order models and in human clinical trials.
The DBA1/j mouse model was selected due to the aforementioned
similarities with human disease, as compared with immune compromised
models, such as AG129 mice and suckling mouse models that often include
lethality and neurologic symptoms that are generally atypical disease
manifestations in human patients. We have not identified any features of
chronic infection, which would be very important to further model clinically
relevant human disease (Poo et al., 2014), although indication of chronic
infection has been observed in other mouse models (Seymour et al., 2015).
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Our results indicate that prophylactic treatment with mDEF201, even
several weeks in advance, may be a viable option during a CHIK epidemic,
especially in the absence of a vaccine. Future studies should focus on the
therapeutic window of pre-treatment with mDEF201 to discuss the potential
of treating at-risk naïve populations, then studies need to be elevated in
model level possibly using the hamster model which treats with a human
DEF201, to test for efficacy.
Studies conducted with GP1681 demonstrate the importance and
complexities involved with the CHIKV immunologic response and the
involvement of various cytokines during different phases of CHIKV
infection (Partidos et al., 2011). Levels of IL-6 are significantly increased in
mouse models of CHIKV infection, which prompted the selection of ACT to
determine if reducing IL-6 would positively impact infection. Treatment
with 40 mg/ml was effective in improving disease, suggesting a role of IL-6
in pathogenesis. Similar results were seen with Bindarit, an MCP-1 inhibitor,
which was protective in C57BL/6 mice infected with CHIKV (Rulli et al.,
2011). This supports targeting of specific inflammatory mediators in order to
ameliorate disease after CHIKV infection, although the timing of treatment
is likely very critical.
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Overall, we have provided evidence that treatment with immune
modulators may be beneficial to patient outcome after CHIKV infection.
Currently researchers are working on producing vaccines to CHIKV but
rapid gene mutations make this difficult. Anti-viral testing is currently being
done to target specific phases of viral infection, this research should be
continued and special emphasis placed on CHIK because of the rapidity with
which it is spreading.

84

5.1 References
Partidos, C.D., Weger, J., Brewoo, J., Seymour, R., Borland, E.M.,
Ledermann, J.P., Powers, A.M., Weaver, S.C., Stinchcomb, D.T., Osorio,
J.E., 2011. Probing the attenuation and protective efficacy of a candidate
chikungunya virus vaccine in mice with compromised interferon (IFN)
signaling. Vaccine 29, 3067-3073.
Poo, Y.S., Rudd, P.A., Gardner, J., Wilson, J.A., Larcher, T., Colle, M.A.,
Le, T.T., Nakaya, H.I., Warrilow, D., Allcock, R., Bielefeldt-Ohmann, H.,
Schroder, W.A., Khromykh, A.A., Lopez, J.A., Suhrbier, A., 2014. Multiple
immune factors are involved in controlling acute and chronic chikungunya
virus infection. PLoS Negl Trop Dis 8, e3354.
Rulli, N.E., Rolph, M.S., Srikiatkhachorn, A., Anantapreecha, S.,
Guglielmotti, A., Mahalingam, S., 2011. Protection from arthritis and
myositis in a mouse model of acute chikungunya virus disease by bindarit,
an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 204,
1026-1030.
Seymour, R.L., Adams, A.P., Leal, G., Alcorn, M.D., Weaver, S.C., 2015. A
Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with
Features of Persistence, for Vaccine Safety Evaluation. PLoS Negl Trop Dis
9, e0003800.

85

USE OF COPYRIGHTED MATERIAL
ELSEVIER LICENSE
TERMS AND CONDITIONS
Jul 15, 2016

This Agreement between Ashley Dagley ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number

3907751278814

License date

Jul 14, 2016

Licensed Content Publisher Elsevier
Licensed Content
Publication

Antiviral Research

Licensed Content Title

Protection against Chikungunya virus induced arthralgia following
prophylactic treatment with adenovirus vectored interferon
(mDEF201)

Licensed Content Author

Ashley Dagley,Jane Ennis,Jeffrey D. Turner,Kerry A. Rood,Arnaud
J. Van Wettere,Brian B. Gowen,Justin G. Julander

Licensed Content Date

August 2014

Licensed Content Volume
Number

108

Licensed Content Issue
Number

n/a

Licensed Content Pages

9

Start Page

1

End Page

9

Type of Use

reuse in a thesis/dissertation

Portion

full article

Format

both print and electronic

Are you the author of this
Elsevier article?

Yes

Will you be translating?

No

Order reference number

86
Title of your
thesis/dissertation

Amelioration of chikungunya through inhibition of the
inflammatory respobse

Expected completion date

Aug 2016

Estimated size (number of
pages)

99

Elsevier VAT number

GB 494 6272 12

Requestor Location

Ashley Dagley
649 Canyon Rd
LOGAN, UT 84321
United States
Attn: Ashley Dagley

